Michael Mark
Neurology · Millsboro, DENPI 1821082892
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 186 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,128 and has fallen 73.6% since, to $297 in 2023.
Across 186 payments — averaging $13.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$439
- Biohaven Pharmaceutical Holding Company Ltd.$354
- Teva Pharmaceuticals USA, Inc.$312
- AbbVie$272
- Biogen$133
- EMD Serono, Inc.$122
- plus $909 from 15 others
What the payments were for
- Food & beverage$2,540100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 49 | $439 |
| Biohaven Pharmaceutical Holding Company Ltd. | 33 | $354 |
| Teva Pharmaceuticals USA, Inc. | 21 | $312 |
| AbbVie | 21 | $272 |
| Biogen | 7 | $133 |
| EMD Serono, Inc. | 5 | $122 |
| Amgen | 5 | $113 |
| Neurocrine Biosciences, Inc. | 5 | $104 |
| Eisai Inc. | 6 | $102 |
| E.r. Squibb & Sons, L.L.C. | 6 | $102 |
| Bristol Myers Squibb | 6 | $101 |
| Novartis | 6 | $97 |
| Tanabe Pharma America, Inc. | 3 | $66 |
| Sunovion Pharmaceuticals Inc. | 4 | $58 |
| AstraZeneca | 2 | $41 |
| Lundbeck LLC | 2 | $39 |
| Neurelis, Inc. | 1 | $18 |
| Pfizer | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| CSL Behring | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
How this compares
$2,540 in reported general payments places this provider in the 70th percentile of 61 neurology providers in Delaware.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Primidone | 11 | $160 |
| Topiramate | 11 | $93 |
Paid to pharmacies, not to this prescriber.
Other neurology in Millsboro
- Justin MartelloNewark$485K
- Abraham ScheerDover$231K
- Jason SilversteenNewark$202K
- Jay DaveMilford$161K
- Lawrence KempLewes$24K
- Etsegenet TizazuNewark$15K
- William SommersNewark$14K
- Lee DresserNewark$12K
- John PollardNewark$7K
- Shilpa KautaNewark$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.